The FDA on November 19, 2025, approved KOSELUGO® for adults with NeuroFibromatosis type 1 (NF1) who have symptomatic, inoperable Plexiform Neurofibromas (PN). FDA previously approved KOSELUGO® capsules and granules for pediatric patients 1 year of age and older for this indication. KOSELUGO® is a product of AstraZeneca Pharmaceuticals LP.
Bottom Ad
Advertisement
Subscribe
